Anissa Thomas
Adult Health · Birmingham, ALNPI 1275732570
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 435 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,208, 3.2 times the $1,018 reported in 2021. Among adult health clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 435 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- Alkermes, Inc.$1K
- Lundbeck LLC$842
- E.r. Squibb & Sons, L.L.C.$672
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$619
- plus $2K from 10 others
What the payments were for
- Food & beverage$7,51598%
- Education$1562%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 98 | $1,376 |
| Neurocrine Biosciences, Inc. | 58 | $1,171 |
| Alkermes, Inc. | 62 | $1,122 |
| Lundbeck LLC | 45 | $842 |
| E.r. Squibb & Sons, L.L.C. | 46 | $672 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 32 | $619 |
| Teva Pharmaceuticals USA, Inc. | 29 | $560 |
| Johnson & Johnson | 13 | $308 |
| Vanda Pharmaceuticals Inc. | 15 | $297 |
| Indivior Inc. | 12 | $207 |
| Sunovion Pharmaceuticals Inc. | 11 | $203 |
| AbbVie | 10 | $191 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $51 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Luye Pharma (USA) Ltd. | 1 | $20 |
| Adlon Therapeutics L.p. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$123
How this compares
$7,672 in reported general payments places this provider in the 90th percentile of 308 adult health providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 298 | $824,591 |
| Abilify MaintenaAripiprazole | 202 | $573,009 |
| AustedoDeutetrabenazine | 51 | $328,217 |
| IngrezzaValbenazine Tosylate | 30 | $241,638 |
| Invega TrinzaPaliperidone Palmitate | 20 | $190,992 |
| AristadaAripiprazole Lauroxil | 23 | $76,651 |
| RexultiBrexpiprazole | 47 | $72,574 |
| Wellbutrin XlBupropion Hcl | 26 | $63,720 |
| CaplytaLumateperone Tosylate | 32 | $53,254 |
| VraylarCariprazine Hcl | 23 | $32,538 |
| PerserisRisperidone | 14 | $29,736 |
| Aripiprazole | 376 | $28,394 |
| Clozapine | 206 | $26,074 |
| LybalviOlanzapine/Samidorphan Malate | 13 | $23,837 |
| Perphenazine | 52 | $10,147 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $308 | $1,015,583318 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,376 | $645,583249 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $560 | $328,21751 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,171 | $241,63830 claims |
| Alkermes, Inc.Aristada, Lybalvi | $1,122 | $100,48836 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $619 | $53,25432 claims |
| AbbVieVraylar | $191 | $32,53823 claims |
| Indivior Inc.Perseris | $207 | $29,73614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 308 adult health providers in Alabama.
Other adult health in Birmingham
- Lanier OhareBirmingham$42K
- Jessica WrightBirmingham$33K
- Sara HopperBirmingham$21K
- Andrea SuttonBirmingham$21K
- Laura RomundstadBirmingham$10K
- Jane DavisBirmingham$9K
- Chelsey KahlerBirmingham$5K
- Mary WadeBirmingham$5K
- Merry WoodsBirmingham$4K
- Taneaka Rowe-HouserBirmingham$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.